COVID-19 in Patients with Primary Biliary Cholangitis
The aim of the study. To analyze the course of COVID-19 infection in patients with primary biliary cholangitis (PBC).Materials and methods. In a single-center retrospective study, survey and analysis of medical records of 144 patients with PBC was carried out.Results. All patients (n = 144) received...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2022-09-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/686 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860054449717248 |
|---|---|
| author | М. К. Prashnova K. L. Raikhelson N. V. Marchenko S. M. Zakharenko |
| author_facet | М. К. Prashnova K. L. Raikhelson N. V. Marchenko S. M. Zakharenko |
| author_sort | М. К. Prashnova |
| collection | DOAJ |
| description | The aim of the study. To analyze the course of COVID-19 infection in patients with primary biliary cholangitis (PBC).Materials and methods. In a single-center retrospective study, survey and analysis of medical records of 144 patients with PBC was carried out.Results. All patients (n = 144) received basic therapy with ursodeoxycholic acid (UDCA), 5 of them received fibrates as well. Response to therapy (EASL criteria) was obtained in 30 people. Between March 2020 and March 2021, 50 patients (34.7 %) suffered COVID-19, with mean age of 58.8 ± 10.7 years, 16 of which were diagnosed with liver cirrhosis. Mild COVID-19 was observed in 34 (68 %) people, moderate course — in 14 (28 %), severe — in 2 (4 %), cases of extremely severe course were not recorded. 12 patients were hospitalized, 8 of which received oxygen therapy due to a decrease in SpO2 < 94 %, there was no need for the use of other methods of oxygen therapy in any case. The duration of hospitalization was 11.4 ± 5.7 days. There was a higher initial activity of serum alkaline phosphatase (1.8 ± 1.0 versus 1.7 ± 1.4 times of the upper limit of normal, M ± SD, p = 0.04) in patients with COVID-19 infection and lack of UDCA therapy effectiveness was more prominent (40 % vs. 19.1 % of cases, p = 0.04) compared with patients who did not have COVID-19. There were no significant differences in characteristics of the course of PBC (stage, response to therapy) and age in correlation with severity of the course of COVID-19. Among hospitalized patients and those in need of oxygen support, large proportion were older patients (58.3 % and 62.5 %, respectively) and patients with concomitant diseases (62.5 % and 75 %, respectively). Patients who hadn`t previously responded to UDCA therapy were more likely to require oxygen support compared to patients responding to basic therapy (p < 0.01).Conclusion. PBC is not a risk factor for severe COVID-19. A protective effect of UDCA in SARS-CoV-2 infection is possible, which requires further investigation. |
| format | Article |
| id | doaj-art-7e2c63f0ef8f4d4c8c53d8b5eca59585 |
| institution | Kabale University |
| issn | 1382-4376 2658-6673 |
| language | Russian |
| publishDate | 2022-09-01 |
| publisher | Gastro LLC |
| record_format | Article |
| series | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| spelling | doaj-art-7e2c63f0ef8f4d4c8c53d8b5eca595852025-02-10T16:14:37ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732022-09-01323293410.22416/1382-4376-2022-32-3-29-34489COVID-19 in Patients with Primary Biliary CholangitisМ. К. Prashnova0K. L. Raikhelson1N. V. Marchenko2S. M. Zakharenko3St. Petersburg State UniversitySt. Petersburg State UniversitySt. Petersburg State UniversityS.M. Kirov Military Medical AcademyThe aim of the study. To analyze the course of COVID-19 infection in patients with primary biliary cholangitis (PBC).Materials and methods. In a single-center retrospective study, survey and analysis of medical records of 144 patients with PBC was carried out.Results. All patients (n = 144) received basic therapy with ursodeoxycholic acid (UDCA), 5 of them received fibrates as well. Response to therapy (EASL criteria) was obtained in 30 people. Between March 2020 and March 2021, 50 patients (34.7 %) suffered COVID-19, with mean age of 58.8 ± 10.7 years, 16 of which were diagnosed with liver cirrhosis. Mild COVID-19 was observed in 34 (68 %) people, moderate course — in 14 (28 %), severe — in 2 (4 %), cases of extremely severe course were not recorded. 12 patients were hospitalized, 8 of which received oxygen therapy due to a decrease in SpO2 < 94 %, there was no need for the use of other methods of oxygen therapy in any case. The duration of hospitalization was 11.4 ± 5.7 days. There was a higher initial activity of serum alkaline phosphatase (1.8 ± 1.0 versus 1.7 ± 1.4 times of the upper limit of normal, M ± SD, p = 0.04) in patients with COVID-19 infection and lack of UDCA therapy effectiveness was more prominent (40 % vs. 19.1 % of cases, p = 0.04) compared with patients who did not have COVID-19. There were no significant differences in characteristics of the course of PBC (stage, response to therapy) and age in correlation with severity of the course of COVID-19. Among hospitalized patients and those in need of oxygen support, large proportion were older patients (58.3 % and 62.5 %, respectively) and patients with concomitant diseases (62.5 % and 75 %, respectively). Patients who hadn`t previously responded to UDCA therapy were more likely to require oxygen support compared to patients responding to basic therapy (p < 0.01).Conclusion. PBC is not a risk factor for severe COVID-19. A protective effect of UDCA in SARS-CoV-2 infection is possible, which requires further investigation.https://www.gastro-j.ru/jour/article/view/686primary biliary cholangitiscovid-19coronavirus infectionliver diseaseursodeoxycholic acid |
| spellingShingle | М. К. Prashnova K. L. Raikhelson N. V. Marchenko S. M. Zakharenko COVID-19 in Patients with Primary Biliary Cholangitis Российский журнал гастроэнтерологии, гепатологии, колопроктологии primary biliary cholangitis covid-19 coronavirus infection liver disease ursodeoxycholic acid |
| title | COVID-19 in Patients with Primary Biliary Cholangitis |
| title_full | COVID-19 in Patients with Primary Biliary Cholangitis |
| title_fullStr | COVID-19 in Patients with Primary Biliary Cholangitis |
| title_full_unstemmed | COVID-19 in Patients with Primary Biliary Cholangitis |
| title_short | COVID-19 in Patients with Primary Biliary Cholangitis |
| title_sort | covid 19 in patients with primary biliary cholangitis |
| topic | primary biliary cholangitis covid-19 coronavirus infection liver disease ursodeoxycholic acid |
| url | https://www.gastro-j.ru/jour/article/view/686 |
| work_keys_str_mv | AT mkprashnova covid19inpatientswithprimarybiliarycholangitis AT klraikhelson covid19inpatientswithprimarybiliarycholangitis AT nvmarchenko covid19inpatientswithprimarybiliarycholangitis AT smzakharenko covid19inpatientswithprimarybiliarycholangitis |